RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · Real-Time Price · USD
0.9174
+0.0312 (3.52%)
At close: Nov 28, 2025, 1:00 PM EST
0.9000
-0.0174 (-1.90%)
After-hours: Nov 28, 2025, 4:30 PM EST
RenovoRx Revenue
RenovoRx had revenue of $266.00K in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $928.00K. In the year 2024, RenovoRx had annual revenue of $43.00K.
Revenue (ttm)
$928.00K
Revenue Growth
n/a
P/S Ratio
32.08
Revenue / Employee
$92,800
Employees
10
Market Cap
33.62M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 43.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
RNXT News
- 10 days ago - RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th - GlobeNewsWire
- 16 days ago - RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update - GlobeNewsWire
- 23 days ago - RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD - GlobeNewsWire
- 25 days ago - RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th - GlobeNewsWire
- 4 weeks ago - RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET - GlobeNewsWire
- 7 weeks ago - RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD - GlobeNewsWire
- 2 months ago - RenovoRx's PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites - GlobeNewsWire
- 2 months ago - RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th - GlobeNewsWire